Catalyst Pharmaceuticals (CPRX) Free Cash Flow Growth (5y) (2015 - 2026)
Catalyst Pharmaceuticals (CPRX) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82.99% |
| Dec 31, 2025 | 27.90% |
| Sep 30, 2025 | 23.15% |
| Jun 30, 2025 | 39.97% |
| Mar 31, 2025 | 52.78% |
| Dec 31, 2024 | 41.93% |
| Sep 30, 2024 | 34.88% |
| Jun 30, 2024 | 35.46% |
| Mar 31, 2024 | 42.88% |
| Dec 31, 2023 | 53.81% |
| Sep 30, 2023 | 53.27% |
| Jun 30, 2023 | 53.21% |
| Mar 31, 2023 | 31.77% |
| Dec 31, 2022 | 64.22% |
| Sep 30, 2022 | 77.64% |
| Jun 30, 2022 | 59.06% |
| Mar 31, 2022 | 33.15% |
| Dec 31, 2021 | 44.64% |
| Sep 30, 2021 | 53.78% |
| Jun 30, 2021 | 41.18% |